2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Canada.ca  Health  Healthy living  Vaccines and immunization

 National Advisory Committee on Immunization (NACI): Statements and publications

National Advisory Committee on

Immunization (NACI): Workplan

Statements and publications

About us

Meetings

Workplan

Methods and process

Related links

Terms of reference

1 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Canadian Immunization Guide

On this page
• Preamble
• 2022-2024 workplan
• Abbreviations
• Previous workplans

Preamble
The following list represents policy questions for the National Advisory
Committee on Immunization for 2022-2024. When combined with the
added work of COVID-19 related topics, it is acknowledged that not all of
these topics will be addressed over these two years, so some will be
carried forward to subsequent years. This list however represents priority
selections to be undertaken by NACI as capacity is freed up from
COVID-19 vaccine issues over time.

The priority selections below have been informed by consultations with
NACI and Provincial and Territorial stakeholders. As new products and
indications are authorized in Canada or new information becomes
available, workplan items may be added for consideration and priorities
may change. This is particularly true in the pandemic environment,
where workplanning outside of COVID-19 vaccines continues to be
unpredictable.

The following triggers may drive items for the NACI workplan:

2 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

• New vaccine or new indication
• New Canadian recommendations (e.g., CATMAT, CPS, SOGC, P/Ts,
etc.)
• Recommendation adopted by other reputable organizations
• P/T programmatic concerns
• New safety signal detected
• Vaccine supply issue
• Changes in disease epidemiology
• CIG chapter review
• Publication of key trials
• Internal inconsistency
• Update to product monograph
• Public health emergency
• Work already in progress that was interrupted by the COVID-19
pandemic work

2022-2024 workplan
Initiative Policy / Program issues Trigger(s)

Work currently underway

COVID-19 Updated guidance on priority Public health

immunization strategies and emergency
associated target populations
based on current evidence and
authorized COVID-19 vaccines.

3 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Initiative Policy / Program issues Trigger(s)

Updated recommendations on New vaccines
the use of authorized
COVID-19 vaccines as they are
approved for use in Canada,
and as evidence on these
vaccines and COVID-19 evolves

CIG COVID-19 Chapter reviews CIG chapter
reviews;
new Statement
content

High- Update smallpox vaccine Recommendation

Consequence guidance for lab workers and adoption by
Infectious outbreak situations, including reputable
Diseases (HCID) consideration of other organization
orthopox viruses (e.g.
Public health
monkeypox)
emergency

Pneumococcal Recommendations for new New vaccine

adult pneumococcal vaccines
(PCV15 and PCV20) relative to
existing options, dependent on
regulatory decisions

Seasonal Repeated seasonal influenza P/T programmatic

influenza vaccination concerns

Optimal timing of seasonal P/T programmatic
influenza programs (including concerns
intra-season waning)

4 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Initiative Policy / Program issues Trigger(s)

Guidance on seasonal Public health
influenza vaccination in the emergency
context of COVID-19

2023-2024 Seasonal Influenza P/T programmatic
Statement concerns

Review of safety and P/T programmatic
effectiveness of influenza concerns
vaccine in pregnancy

Review of product choice for P/T programmatic
65+ concerns

2024-2025 Seasonal Influenza P/T programmatic
Statement concerns

Supplemental statements or New vaccine
Addenda for new products
and/or NACI opinions related
to new or existing products

Canadian Blood products, human CIG chapter review

Immunization immunoglobulin and timing of
Guide (CIG): immunization - completion of
Part 1 revision
(Key
Communicating effectively CIG chapter review
Immunization
about immunization - due for
Information)
revision

Updates to various chapters CIG chapter review
related to COVID-19 vaccine
content

5 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Initiative Policy / Program issues Trigger(s)

CIG: Part 3 The following chapters will be CIG chapter review

(Special due for revision: 1)
Populations) Immunization of Adults; 2)
Immunization of persons with
inadequate immunization
records; 3) Immunization of
infants born prematurely; 4)
Immunization of patients in
healthcare institutions; 5)
Immunization of persons new
to Canada; 6) Immunization of
workers

CIG: Part 4 Part 4 chapters requiring CIG chapter review

(Active updates are those
Vaccines) withnplanned NACI statements

Next projects

Human Consider 1-dose HPV Recommendation

Papillomavirus vaccination schedule, and adoption by
(HPV) consider 2-dose/3-dose reputable
schedules among persons 15+ organization

Pneumococcal Recommendations for new New indication

pediatric pneumococcal
vaccines (PCV15 and PCV20)
relative to existing options,
dependent on regulatory
submission and decisions

Future projects, depending on trajectory of COVID-19 pandemic
and associated vaccines (in order of prioritization)

6 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Initiative Policy / Program issues Trigger(s)

Respiratory New active RSV vaccines or New vaccine

Syncytial Virus prophylactic monoclonal
(RSV) antibodies, dependent on
regulatory submission and
decisions

Rabies Updated guidance on rabies Recommendation

vaccine pre-exposure adoption by
prophylaxis (PrEP) and post- reputable
exposure prophylaxis (PEP) in organization
context of new guidance from Work already in
WHO progress that was
interrupted by the
COVID-19
pandemic work

Hepatitis A Consider a universal hepatitis Recommendation

A vaccine schedule, including adoption by
1-dose option reputable
organization

Herpes Zoster Recombinant Zoster Vaccine New indication

(RZV) use in
immunocompromised
populations (new indication for
those under 50 years old at
high risk of disease)

Meningococcal Recommendations on use of New vaccine

new Meningococcal (Groups A,
C, Y, W) Polysaccharide Tetanus
Toxoid Conjugate Vaccine

7 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

Initiative Policy / Program issues Trigger(s)

Hepatitis B Recommendations on use of New vaccine

3-antigen Hepatitis B Vaccine
Candidate

Abbreviations
NACI National Advisory Committee on Immunization

CATMAT Committee to Advise on Tropical Medicine and Travel

CIC Canadian Immunization Committee

CIG Canadian Immunization Guide

CPS Canadian Paediatric Society

HPV Human Papillomavirus

P/Ts Provinces and territories

PEP Post-exposure prophylaxis

PrEP Pre-exposure prophylaxis

RSV Respiratory Syncytial Virus

RZV Recombinant Zoster Vaccine

SOGC Society of Obstetricians and Surgeons of Canada

8 of 9 4/13/23, 20:50
2022 to 2024 workplan: National Advisory Committee o... https://www.canada.ca/en/public-health/services/immuniz...

WHO World Health Organization

Previous workplans
▸ 2020-2021

▸ 2019-2020

Date modified:
2022-06-28

9 of 9 4/13/23, 20:50